3-Substituted Thietane-1,1-Dioxides: Synthesis, Antidepressant Activity, and in Silico Prediction of Their Pharmacokinetic and Toxicological Properties
- 82 Downloads
3-Aryloxy- and 3-phenylsulfanylthietane-1,1-dioxides were synthesized by reacting 3,5-dibromo-1-(1,1-dioxothietan-3-yl)-1,2,4-triazole with sodium phenolates and thiophenolate. The 5-aryloxy- and 5-arenesulfonyl-3-bromo-1-(1,1-dioxothietan-3-yl)-1,2,4-triazoles were synthesized via oxidation by H2O2 of 5-aryloxy- and 5-phenylsulfanyl-3-bromo-1,2,4-triazoles containing thietane or thietane oxide rings. The 3-substituted thietane-1,1-dioxide IId (2 and 20 mg/kg) displayed antidepressant properties in tail-suspension (TST) and forced-swim tests (FST) that were comparable with those of imipramine. Low toxicity risks (mutagenicity, tumorigenicity, irritation, reproductive toxicity) and satisfactory pharmacokinetic characteristics (correspondence to Lipinski’s rule of five) were predicted (Osiris Property Explorer, Molinspiration) for it.
Keywords
thietanes 1,2,4-triazoles antidepressant activity prediction Lipinski’s rule of fiveReferences
- 1.Global Burden of Disease: Generating Evidence, Guiding Policy, Europe and Central Asia Regional Edition, Human Development Network, World Bank, Institute for Health Metrics and Evaluation, Seattle, WA, 2013; http: // www-wds.worldbank. org / external / default / WDSContentServer / IW3P / IB / 2013 / 09 / 03 / 000456288 20130903105621 / Rendered / PDF / 808480PUB0RUSS0Box0379820B00PUBLIC0.pdfGoogle Scholar
- 2.V. S. Yastrebov, I. A. Mitikhina, V. G. Mitikhin, et al., Zh. Nevrol. Psikhiatr. im. S. S. Korsakova, No. 2, 4 – 13 (2012).Google Scholar
- 3.J. C. Fournier, R. J. DeRubeis, S. D. Hollon Dimidjian, et al., J. Am. Med. Assoc., 303(1), 47 – 53 (2010).CrossRefGoogle Scholar
- 4.O. A. Ivanova, I. L. Nikitina, et al., RU Pat. 2,424,799, Jul. 27, 2011; Byull. Izobret., No. 21 (2011); http: // www1.fips.ru / Archive / PAT / 2011FULL / 2011.07.21 / DOC / RUNWC1 / 000 / 000 / 002 / 424 / 799 / document.pdf
- 5.E. E. Klen, N. N. Makarova, F. A. Khaliullin, et al., Bashk. Khim. Zh., 15(4), 112 – 114 (2008).Google Scholar
- 6.I. L. Nikitina, R. A. Gabidullin, E. E. Klen, et al., Khim.-farm. Zh., 46(4), 17 – 22 (2012); Pharm. Chem. J., 46(4), 213 – 218 (2012).Google Scholar
- 7.E. E. Klen, F. A. Khaliullin, and N. N. Makarova, Zh. Org. Khim., 44(11), 1729 – 1731 (2008).Google Scholar
- 8.E. Block, in: Comprehensive Heterocyclic Chemistry, Vol. 7, A. R. Katritzky and C. W. Rees (eds.), Oxford, New York (1997), pp. 403 – 448.Google Scholar
- 9.E. V. Shchetinin, V. A. Baturin, E. B. Arushanyan, et al., Zh. Vyssh. Nervn. Deyat., No. 5, 958 – 964 (1989).Google Scholar
- 10.D. C. Young, Computational Drug Design, John Wiley & Sons Inc., Hoboken, New Jersey (2009).CrossRefGoogle Scholar
- 11.C. A. Lipinsky, F. Lombardo, B. W. Dominy, and P. J. Feeney, Adv. Drug Delivery Rev., 46, 3 – 26 (2001).CrossRefGoogle Scholar
- 12.C. A. Lipinsky, J. Pharmacol. Toxicol. Methods, 44, 235 – 249 (2000).CrossRefGoogle Scholar
- 13.P. Ertl, B. Rohde, and P. Selzer, J. Med. Chem., 43(20), 3714 – 3717 (2000).CrossRefPubMedGoogle Scholar
- 14.
- 15.Y. H. Zhao, M. H. Abraham, J. Le, A. Hersey, et al., Pharm. Res., 19(10), 1446 – 1457 (2002).CrossRefPubMedGoogle Scholar
- 16.
- 17.R. D. Porsolt, M. L. Pichon, and M. Jalfre, Nature, 266, 730 – 732 (1977).CrossRefPubMedGoogle Scholar
- 18.L. Steru, R. Chermat, B. Thierry, et al., Psychopharmacology (Berlin, Ger.), 85(3), 367 – 370 (1985).Google Scholar
- 19.R. A. Gabidullin, O. A. Ivanova, I. L. Nikitina, et al., State Registration Certificate for Computer Program No. 2008610170, Moscow (2008).Google Scholar
- 20.S. Glantz, Primer of Biostatistics, McGraw-Hill, New York (1997) [Russian translation, Praktika, Moscow (1998)].Google Scholar